Publications by authors named "Anne-Pham Ledard"
Article Synopsis
- - The study investigates primary cutaneous marginal zone lymphoma (PCMZL) by analyzing recurrent cases to determine whether it's a reactive process or a true lymphoma, utilizing data from the French Study Group of Cutaneous Lymphoma (GFELC).
- - Methods included assessing histology, B-cell clonality, and immunophenotype of lesions, revealing that most initial cases were localized, with differences in recurrence times based on location, and certain clonal patterns were more prominent in local recurrences.
- - The findings suggest that assessing immunoglobulin phenotype, particularly IgM and IgD, may be critical for diagnosing PCMZL, as IgM-positive cases tend to lead to more aggressive transformation and poorer prognosis, indicating different biological
Introduction: Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI treatment and after ICI discontinuation and (2) to assess how ICI-IA influences ICI management across time.
Methods: All ICI-treated patients referred to rheumatology at Bordeaux University Hospital were identified and patients with ICI-IA with a follow-up of≥6months after ICI-IA onset were included.
Immune checkpoint inhibitors (ICIs) present clinicians with the challenge of managing immune-related adverse events (irAEs), which can range from mild to severe due to immune system activation . While guidelines recommend discontinuing ICIs for grade 3 partial and all grade 4 irAEs, there is growing interest in rechallenging patients based on oncological outcomes, particularly for cardiovascular and neurological irAEs where data remains scarce . We retrospectively evaluated the safety of ICI rechallenge following grade 3-4 irAEs, specifically focusing on cardiovascular and neurological events, in patients discussed at our multidisciplinary immunotoxicity assessment board between 2019 and 2021.
View Article and Find Full Text PDFArticle Synopsis
- Sézary syndrome is a rare and deadly skin cancer, and this study looked into the survival rates and factors affecting outcomes, particularly focusing on the treatment mogamulizumab.
- *The research analyzed data from 339 patients diagnosed between 2000 and 2020 across Europe, highlighting that age over 80 and large-cell transformation worsened survival rates.
- *Results indicated that patients treated with mogamulizumab had significantly lower mortality rates, suggesting it is an effective treatment option for Sézary syndrome.
Purpose: Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer in white-skinned populations. There is little information on the epidemiology of cSCC, and even less on advanced cases (acSCC). Therefore, we analyzed acSCC patients to describe their characteristics, management, and outcomes over time.
View Article and Find Full Text PDFPurpose: While several studies reported the influence of co-medications on immune checkpoint therapy and chemotherapy, it remains poorly studied with targeted therapy. Targeted therapies inhibiting BRAF and MEK had significantly improved management of advanced melanoma with BRAFV600 mutation over the last decade, we aimed to investigate the possible influence of co-mediations on the efficacy and toxicity of these targeted therapies (TT).
Methods: We conducted an observational study identifying patients with advanced melanoma treated with BRAF/MEK inhibitors between 2013 and 2020 in the Bordeaux University Hospital.
Objective: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge.
Methods: We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals.
Article Synopsis
- The study evaluated the effectiveness and safety of the drug omalizumab for treating bullous pemphigoid (BP) in patients who did not respond to standard treatments, analyzing data from 100 patients across 18 medical centers in France from 2014 to 2021.
- 77% of patients achieved complete remission (CR), and 9% achieved partial remission, with a median time to CR of approximately 3 months, although 14% experienced relapses within a median follow-up of 12 months.
- Higher baseline levels of anti-BP180-NC16A IgE were linked to better CR outcomes, while other factors like urticarial lesions or eosinophil
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cutaneous tumor with high metastatic potential. In rare cases, it can be associated with paraneoplastic syndromes (PNS), which result from an antitumor immunity against antigens produced by the tumor itself. Lambert-Eaton Myasthenic Syndrome (LEMS) is a neurological autoimmune PNS characterized by an impairment of the neuromuscular junction, leading to proximal muscle weakness and fatigability.
View Article and Find Full Text PDFBackground: Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs.
View Article and Find Full Text PDFArticle Synopsis
- BRAF V600 wild-type advanced melanomas have limited treatment options after immunotherapy fails, but trametinib, a MEK inhibitor, is one possible option.
- In a study of 22 patients, 36% had some control of their disease after using trametinib, but it mostly lasted only a couple of months.
- Many patients experienced side effects like skin rashes and tiredness, so doctors and patients should carefully consider this treatment together.
Background: Adverse pregnancy outcomes (APO) occur in 35% of patients with pemphigoid gestationis (PG). No biological predictor of APO has been established yet.
Objectives: To assess a potential relationship between the occurrence of APO and the serum value of anti-BP180 antibodies at the time of PG diagnosis.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can rarely cause a serious skin reaction known as drug reactions with eosinophilia and systemic symptoms (DRESS), and this study aims to outline its clinical features, treatment, and prognosis.
- The study analyzed 13 patients who reported DRESS after ICI treatment, noting symptoms like fever, skin rash, and facial swelling, with a median onset of 22 days after starting the medication.
- Treatment typically involved stopping the ICI and administering systemic steroids, with most patients experiencing moderate severity and no fatalities linked to DRESS; however, a consensus on the best management practices is still needed.
Primary cutaneous large B-cell lymphoma, leg-type (PCLBCL-LT) is the most aggressive primary cutaneous B-cell lymphoma (PCBCL). Tumor microenvironment has a crucial role in tumor development, and tumor-infiltrating lymphocytes (TILs) can be targeted by immunotherapies. We characterized TILs in 20 PCBCLs to identify the tumor microenvironment features associated with clinical outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides, involves the abnormal accumulation of T lymphocytes in the skin.
- CTCL cells exhibit varied characteristics and express cell adhesion molecules like cutaneous lymphocyte antigen (CLA), which facilitates their movement and survival in the skin.
- Research shows that targeting CLA with a specific antibody (HECA-452) reduces the movement, proliferation, and tumor growth of CTCL cells, indicating that inhibiting CLA might offer a potential treatment strategy for CTCL patients.
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with erythroderma, 21 were diagnosed with eczema, 17 with psoriasis, 20 with drug-induced erythroderma, 13 with erythrodermic mycosis fungoides and 20 with Sézary syndrome.
View Article and Find Full Text PDF